The simulation results show that one cannot rely on simple differences between patients in the expression of PD-L1 on the surface of tumor cells, on PD-1 on the surface of T cells, or the tumor immunogenicity, for predicting response to pembrolizumab. This evidence concerns the gene CD274 and neoplasm.